SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose
expansion study designed to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, immunogenicity, and preliminary efficacy of SG2501 in subjects with
relapsed or refractory hematological malignancies and lymphoma.